https://orcid.org/0000-0001-8039-8781
References
- GBD 2019 risk factors collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222.
- Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
- Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. J Hypertens. 2020;38:579–587.
- Cai A, Calhoun DA. Resistant hypertension. An update of experimental and clinical findings. Hypertension. 2017;70:5–9.
- Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events - meta-analyses of randomized trials. J Hypertens. 2016;34:1451–1463.
- Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific committee of the Italian pharmacoepidemiological survey on antihypertensive therapy. J Hypertens. 2000;18:1691–1699.
- Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens. 2007;29:553–562.
- Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population based study in the elderly. Am J Hypert. 1997;10:697–704.
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–1357.
- Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–1152.
- Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25:885–892.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;139:e1082–e1143.
- Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016 Feb 15;205:147–156.
- Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol. 2014;64:613–621.
- Thom S, Field J, Poulter N, et al. Use of a multidrug pill in reducing cardiovascular events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol. 2014;21:252–261.